Astaxanthin reduces type 2 diabetic‑associated cognitive decline in rats via activation of PI3K/Akt and attenuation of oxidative stress

Li,Xiaobin; Qi,Zhonghua; Zhao,Longshan; Yu,Zhan

doi:10.3892/mmr.2015.4615

Astaxanthin reduces type 2 diabetic‑associated cognitive decline in rats via activation of PI3K/Akt and attenuation of oxidative stress

Authors:
- Xiaobin Li
- Zhonghua Qi
- Longshan Zhao
- Zhan Yu
View Affiliations

Affiliations: Department of Emergency, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China, Department of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China, Department of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110034, P.R. China, Department of Pharmacy, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China
Published online on: November 25, 2015 https://doi.org/10.3892/mmr.2015.4615
Pages: 973-979

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Astaxanthin (AST) is an oxygenated derivative of carotenoid, which possesses a strong antioxidant activity. AST can effectively remove active oxygen from the body, and is thus considered to have an important role in disease prevention and treatment. The present study aimed to determine the effects of AST on type 2 diabetic‑associated cognitive decline (DACD) in rats. Rats were intraperitoneally injected with streptozotocin (STZ), in order to establish a model of diabetes mellitus (DM). A total of 40 rats were randomly divided into five groups: The control group, the DM group, the AST (50 mg/kg) group, the AST (100 mg/kg) group, and the AST+LY294002 group (AST, 50 mg/kg and LY, 0.25 µg/100 g). Following a 14‑day treatment with AST, the body weight, blood glucose levels and cognitive function were determined. In addition, the protein expression levels of phosphatidylinositol 3‑kinase (PI3K)/Akt, glutathione peroxidase and superoxide dismutase activity, glutathione and malondialdehyde content, and inducible nitric oxide synthase (iNOS), caspase‑3 and caspase‑9 activity were detected in the rats with DM. AST clearly augmented body weight and reduced blood glucose levels in rats with DM. Furthermore, treatment with AST significantly improved the cognitive function of rats with DM. Treatment with AST activated the PI3K/Akt pathway, and suppressed oxidative stress in the DM rats. In the cerebral cortex and hippocampus of the rats with DM, the activities of iNOS, caspase‑3 and caspase‑9 were markedly reduced. Furthermore, treatment with the Akt inhibitor LY294002 reduced the effectiveness of AST on DACD in rats. In conclusion, AST may reduce type 2 DACD in rats via activation of PI3K/Akt and attenuation of oxidative stress.

View Figures

View References

1	Iwanami J, Mogi M, Tsukuda K, Jing F, Ohshima K, Wang XL, Nakaoka H, Kan-no H, Chisaka T, Bai HY, et al: Possible synergistic effect of direct angiotensin II type 2 receptor stimulation by compound 21 with memantine on prevention of cognitive decline in type 2 diabetic mice. Eur J Pharmacol. 724:9–15. 2014. View Article : Google Scholar
2	Hishikawa N, Yamashita T, Deguchi K, Wada J, Shikata K, Makino H and Abe K: Cognitive and affective functions in diabetic patients associated with diabetes-related factors, white matter abnormality and aging. Eur J Neurol. 22:313–321. 2015. View Article : Google Scholar
3	Wang YB, Wang S, Bai R, Du JL, Xing Q, Ba Y, Yang Y, Zhang XY, Shi CH and Yao JJ: Efficacy of switching from premixed insulin to insulin glargine regimen in Type 2 diabetes mellitus patients with different islet functions. Mol Med Rep. 10:1096–1102. 2014.PubMed/NCBI
4	Lian G, Yue X, Xianxiang Z, Yong L, Weijuan L and Bing C: Insulinization: A promising strategy for the treatment of type 2 diabetes mellitus. Exp Ther Med. 6:1300–1306. 2013.PubMed/NCBI
5	Mossello E, Ballini E, Boncinelli M, Monami M, Lonetto G, Mello AM, Tarantini F, Baldasseroni S, Mannucci E and Marchionni N: Glucagon-like peptide-1, diabetes, and cognitive decline: Possible pathophysiological links and therapeutic opportunities. Exp Diabetes Res. 2011:2816742011. View Article : Google Scholar : PubMed/NCBI
6	Marder TJ, Flores VL, Bolo NR, Hoogenboom WS, Simonson DC, Jacobson AM, Foote SE, Shenton ME, Sperling RA and Musen G: Task-induced brain activity patterns in type 2 diabetes: A potential biomarker for cognitive decline. Diabetes. 63:3112–3119. 2014. View Article : Google Scholar : PubMed/NCBI
7	Liu B, Kuang L and Liu J: Bariatric surgery relieves type 2 diabetes and modulates inflammatory factors and coronary endothelium eNOS/iNOS expression in db/db mice. Can J Physiol Pharmacol. 92:70–77. 2014. View Article : Google Scholar : PubMed/NCBI
8	Zhu KX, Nie SP, Li C, Gong D and Xie MY: Ganoderma atrum polysaccharide improves aortic relaxation in diabetic rats via PI3K/Akt pathway. Carbohydr Polym. 103:520–527. 2014. View Article : Google Scholar : PubMed/NCBI
9	Jia D, Heng LJ, Yang RH and Gao GD: Fish oil improves learning impairments of diabetic rats by blocking PI3K/AKT/nuclear factor-κB-mediated inflammatory pathways. Neuroscience. 258:228–237. 2014. View Article : Google Scholar
10	Lin X, Chen X, Ye J, Li Q, Zhou J, Wu X, Huang Y, Li X, Shi Y, Li S, Li L and Cai H: Association between endogenous secretory receptor for advanced glycation-end products (esRAGE) and carotid intima-media thickness in type 2 diabetes. Exp Clin Endocrinol Diabetes. 122:277–280. 2014. View Article : Google Scholar : PubMed/NCBI
11	Si X, Li P, Zhang Y, Zhang Y, Lv W and Qi D: Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats. Biomed Rep. 2:24–28. 2014.PubMed/NCBI
12	Pietzsch J, Laube M, Bechmann N, Pietzsch FJ and Kniess T: Protective effects of 2,3-diaryl-substituted indole-based cyclooxygenase-2 inhibitors on oxidative modification of human low density lipoproteins in vitro. Clin Hemorheol Microcirc. Dec 29–2014.Epub ahead of print. PubMed/NCBI
13	Price TO, Eranki V, Banks WA, Ercal N and Shah GN: Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice. Endocrinology. 153:362–372. 2012. View Article : Google Scholar :
14	Liu Y, Tian X, Gou L, Sun L, Ling X and Yin X: Luteolin attenuates diabetes-associated cognitive decline in rats. Brain Res Bull. 94:23–29. 2013. View Article : Google Scholar : PubMed/NCBI
15	Stinghen AE, Massy ZA, Vlassara H, Striker GE and Boullier A: Uremic Toxicity of Advanced Glycation End Products in CKD. J Am Soc Nephrol. 2015. View Article : Google Scholar : PubMed/NCBI
16	Jiao L, Stolzenberg-Solomon R, Zimmerman TP, Duan Z, Chen L, Kahle L, Risch A, Subar AF, Cross AJ, Hollenbeck A, et al: Dietary consumption of advanced glycation end products and pancreatic cancer in the prospective NIH-AARP Diet and Health Study. Am J Clin Nutr. 101:126–134. 2015. View Article : Google Scholar
17	Chang CS, Chang CL and Lai GH: Reactive oxygen species scavenging activities in a chemiluminescence model and neuroprotection in rat pheochromocytoma cells by astaxanthin, beta-carotene, and canthaxanthin. Kaohsiung J Med Sci. 29:412–421. 2013. View Article : Google Scholar : PubMed/NCBI
18	Visser H, van Ooyen AJ and Verdoes JC: Metabolic engineering of the astaxanthin-biosynthetic pathway of Xanthophyllomyces dendrorhous. FEMS Yeast Res. 4:221–231. 2003. View Article : Google Scholar : PubMed/NCBI
19	Wu H, Niu H, Shao A, Wu C, Dixon BJ, Zhang J, Yang S and Wang Y: Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases. Mar Drugs. 13:5750–5766. 2015. View Article : Google Scholar : PubMed/NCBI
20	Rao AR, Sindhuja HN, Dharmesh SM, Sankar KU, Sarada R and Ravishankar GA: Effective inhibition of skin cancer, tyrosinase, and antioxidative properties by astaxanthin and astaxanthin esters from the green alga Haematococcus pluvialis. J Agric Food Chem. 61:3842–3851. 2013. View Article : Google Scholar : PubMed/NCBI
21	Chan KC, Pen PJ and Yin MC: Anticoagulatory and antiinflammatory effects of astaxanthin in diabetic rats. J Food Sci. 77:H76–H80. 2012. View Article : Google Scholar : PubMed/NCBI
22	Lee DH, Kim CS and Lee YJ: Astaxanthin protects against MPTP/MPP⁺-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem Toxicol. 49:271–280. 2011. View Article : Google Scholar
23	Sun K, Chang X, Yin L, Li J, Zhou T, Zhang C and Chen X: Expression and DNA methylation status of microRNA-375 in patients with type 2 diabetes mellitus. Mol Med Rep. 9:967–972. 2014.
24	Petty MA and Lo EH: Junctional complexes of the blood-brain barrier. Permeability changes in neuroinflammation. 68:311–323. 2002.
25	Biessels GJ, Deary IJ and Ryan CM: Cognition and diabetes: A lifespan perspective. Lancet Neurol. 7:184–190. 2008. View Article : Google Scholar : PubMed/NCBI
26	Naito Y, Uchiyama K, Aoi W, Hasegawa G, Nakamura N, Yoshida N, Maoka T, Takahashi J and Yoshikawa T: Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice. Biofactors. 20:49–59. 2004. View Article : Google Scholar : PubMed/NCBI
27	Bulhak AA, Jung C, Ostenson CG, Lundberg JO, Sjöquist PO and Pernow J: PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: Involvement of the PI3-Kinase/Akt and NO pathway. Am J Physiol Heart Circ Physiol. 296:H719–H727. 2009. View Article : Google Scholar : PubMed/NCBI
28	You JJ, Yang CH, Yang CM and Chen MS: Cyr61 induces the expression of monocyte chemoattractant protein-1 via the integrin αvβ3, FAK, PI3K/Akt and NF-κB pathways in retinal vascular endothelial cells. Cell Signal. 26:133–140. 2014. View Article : Google Scholar
29	Cho YR, Lim JH, Kim MY, Kim TW, Hong BY, Kim YS, Chang YS, Kim HW and Park CW: Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice. PLoS One. 9:e832042014. View Article : Google Scholar : PubMed/NCBI
30	Malemud CJ: The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis? Future Med Chem. 7:1137–1147. 2015. View Article : Google Scholar : PubMed/NCBI
31	Wang T, Mao X, Li H, Qiao S, Xu A, Wang J, Lei S, Liu Z, Ng KF, Wong GT, et al: N-Acetylcysteine and allopurinol up-regulated the Jak/STAT3 and PI3K/Akt pathways via adiponectin and attenuated myocardial postischemic injury in diabetes. Free Radic Biol Med. 63:291–303. 2013. View Article : Google Scholar : PubMed/NCBI
32	Li Z, Dong X, Liu H, Chen X, Shi H, Fan Y, Hou D and Zhang X: Astaxanthin protects ARPE-19 cells from oxidative stress via upregulation of Nrf2-regulated phase II enzymes through activation of PI3K/Akt. Mol Vis. 19:1656–1666. 2013.PubMed/NCBI
33	Kavitha K, Kowshik J, Kishore TK, Baba AB and Nagini S: Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochim Biophys Acta. 1830.4433–4444. 2013.
34	Zhang XS, Zhang X, Wu Q, Li W, Zhang QR, Wang CX, Zhou XM, Li H, Shi JX and Zhou ML: Astaxanthin alleviates early brain injury following subarachnoid hemorrhage in rats: Possible involvement of Akt/bad signaling. Mar Drugs. 12:4291–4310. 2014. View Article : Google Scholar : PubMed/NCBI
35	Liu YW, Zhu X, Yang QQ, Lu Q, Wang JY, Li HP, Wei YQ, Yin JL and Yin XX: Suppression of methylglyoxal hyperactivity by mangiferin can prevent diabetes-associated cognitive decline in rats. Psychopharmacology (Berl). 228:585–594. 2013. View Article : Google Scholar
36	Wu W, Wang X, Xiang Q, Meng X, Peng Y, Du N, Liu Z, Sun Q, Wang C and Liu X: Astaxanthin alleviates brain aging in rats by attenuating oxidative stress and increasing BDNF levels. Food Funct. 5:158–166. 2014. View Article : Google Scholar
37	Augusti PR, Conterato GM, Somacal S, Sobieski R, Quatrin A, Maurer L, Rocha MP, Denardin IT and Emanuelli T: Astaxanthin reduces oxidative stress, but not aortic damage in atherosclerotic rabbits. J Cardiovasc Pharmacol Ther. 14:314–322. 2009. View Article : Google Scholar : PubMed/NCBI
38	Choi SK, Park YS, Choi DK and Chang HI: Effects of astaxanthin on the production of NO and the expression of COX-2 and iNOS in LPS-stimulated BV2 microglial cells. J Microbiol Biotechnol. 18:1990–1996. 2008.
39	Lee SJ, Bai SK, Lee KS, Namkoong S, Na HJ, Ha KS, Han JA, Yim SV, Chang K, Kwon YG, et al: Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I (kappa)B kinase-dependent NF-kappaB activation. Mol Cells. 16:97–105. 2003.PubMed/NCBI
40	Song X, Wang B, Lin S, Jing L, Mao C, Xu P, Lv C, Liu W and Zuo J: Astaxanthin inhibits apoptosis in alveolar epithelial cells type II in vivo and in vitro through the ROS-dependent mitochondrial signalling pathway. J Cell Mol Med. 18:2198–2212. 2014. View Article : Google Scholar : PubMed/NCBI